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Abstract

serves as an independent risk factor of high in-hospital mortality and
the need for IMV.

Background: Given the high prevalence of obesity around the globe,
patients with coronavirus disease 2019 (COVID-19) are at an increased risk of devastating complications.

Keywords: Body mass index; COVID-19; In-hospital mortality; Invasive mechanical ventilation

Methods: A retrospective cohort study was performed to determine
the association of basal metabolic index (body mass index (BMI))
with the need for invasive mechanical ventilation (IMV), dialysis,
upgrade to an intensive care unit (ICU) and mortality. Independent
t-test and multivariate logistic regression analysis were performed to
calculate mean differences and adjusted odds ratios (aORs) with its
95% confidence interval (CI), respectively.
Results: A total of 176 consecutive patients with confirmed COVID-19
diagnosis were included. The mean age was 62.2 years, with 51% being male patients. The mean BMI for non-surviving patients was significantly higher compared to patients surviving on the seventh day of
hospitalization (35 vs. 30 kg/m2, P = 0.022). Similarly, patients requiring IMV had a higher BMI (33 vs. 29, P = 0.002) compared to nonintubated patients. The unadjusted OR for patients with a higher BMI
requiring IMV (56% vs. 28%, OR: 3.3, 95% CI: 1.6 - 7.0, P = 0.002)
and upgrade to ICU (46% vs. 28%, OR; 2.2, 1.07 - 4.6, P = 0.04) were
significantly higher compared to patients with a lower BMI. Similarly,
patients with a higher BMI had higher in-hospital mortality (21% vs.
9%, OR: 3.2, 95% CI: 1.3 - 8.2, P = 0.01) compared to patients with a
normal BMI. Despite a numerical advantage in the lower BMI group,
there was no significant difference between the two groups in terms of
the need for dialysis (5% vs. 13%, OR: 3.8, 13% vs. 4%, 1.1 - 14.1, P
= 0.07). aORs controlled for baseline comorbidities and medications
mirrored the overall results, except for the need to upgrade to ICU.
Conclusions: In patients with confirmed COVID-19, morbid obesity
Manuscript submitted May 28, 2020, accepted February 3, 2021
Published online April 27, 2021
aAbington

Jefferson Health, Abington, PA, USA
of South Dakota, Vermillion, SD, USA
cThomas Jefferson University, Philadelphia, PA, USA
dCorresponding Author: Waqas Ullah, Department of Internal Medicine,
Abington Jefferson Health, Abington, PA, USA.
Email: waqasullah.dr@gmail.com

Introduction
The USA is the current epicenter of the novel coronavirus pandemic with over 1.6 million cases and nearly 100,000 deaths.
While the true mortality and morbidity caused by coronavirus
disease 2019 (COVID-19) will take years to become apparent, we do know that certain groups of people particularly the
elderly and those with certain comorbidities are at a significantly higher risk of worse outcomes. Among these conditions
is obesity, with the USA currently leading the developed world
in terms of obesity among its citizens (42%), this puts a large
population at measurably higher risk of major complications,
delayed recovery and potentially higher mortality [1, 2].
An analysis of a large cohort of COVID-19 patients by
Lighter et al demonstrated 1.8 and 3.6 times greater probability for admission to critical care units for obese (body mass
index (BMI) 30 - 34.9) and morbidly obese patients (BMI >
35), respectively [3]. Similarly, in a study by Kalligeros et al
and Petrilli et al, BMI ≥ 35 kg/m2 was associated with a significantly higher rate of admission to intensive care unit (ICU)
and need for invasive mechanical ventilation (IMV) [4, 5].
With a high burden of COVID19 and limited healthcare
resources, it is imperative to determine the impact of obesity
not only on in-hospital complications but also on mortality, to
better inform clinical decision making and resource allocation.

Materials and Methods

bUniversity

Study design and participants

doi: https://doi.org/10.14740/jocmr4239

This retrospective cohort study included consecutive adult
inpatients (≥ 18 years old) from Abington Hospital, Jefferson
Health, Pennsylvania, USA. All patients had a confirmed diagnosis of COVID-19 between March 1, 2020, and May 10,
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2020. The study was approved by the Institutional Review
Board (IRB) and the requirement for informed consent was
waived by the Research Ethics Committee (REC). All procedures described in the study have been actuated according to
ethical principles for medical research involving human subject stated in the Declaration of Helsinki.
Data collection
Clinical, demographic, laboratory, treatment, and outcome data
were extracted from electronic medical records (Sunrise) using
a standardized data collection form. All authors contributed to
data retrieval and an independent author adjudicated any difference in interpretation between the data extractors. Severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection in respiratory specimens (throat swabs) was done by
next-generation sequencing or real-time qualitative polymerase chain reaction (RT-qPCR) methods. The laboratory values, cut-off variables and methods for laboratory confirmation
of SARS-CoV-2 infection were standardized. Data regarding
baseline comorbidities included a history of diabetes mellitus
(DM), hypertension (HTN), chronic kidney disease (CKD) and
coronary artery disease (CAD). In hospital medications used
included hydroxychloroquine (HCQ), tocilizumab, steroids and
anticoagulation (AC). Routine blood work included coagulation
profile, complete blood count, serum biochemical tests (renal
function, C-reactive protein (CRP), D-dimer, lactate dehydrogenase (LDH), myocardial enzymes (troponin T (TnT)) and serum
ferritin. Chest radiographs or computed tomography (CT) scans
were also done for most inpatients where clinically indicated.
The criteria for discharge were absence of fever, freedom from
symptoms, and substantial clinical or radiological improvement
for at least 1 day.
Based on the standard definition of the World Health Organization (WHO), patients were divided into two groups,
severely obese population with a BMI > 35 kg/m2 and those
who were not severely obese (BMI < 34.9 kg/m2). Patients
with BMI 18.5 - 24.9 kg/m2 were classified as having a normal
BMI, and those with BMI greater than 40 kg/m2 were noted as
very severely obese.
Statistical analysis
Continuous variables were presented as mean and standard
deviation (SD); categorical variables were reported in percentages and proportions. A Chi-square (χ2) test was used for comparison of categorical data. Fisher exact test was only adopted
if the expected count in more than 20% cells was less than
5. To quantify the association between the dichotomous categorical variables, an unadjusted odds ratio (OR) was obtained
using the Cochran-Mantel-Haenszel method. To explore the
risk factors and gauge the impact of potential effect modifiers
(covariates) on our endpoints (in-hospital death, need for an
upgrade, ventilators and dialysis) binomial and multinomial
logistic regression models were applied as appropriate. The
differences in the baseline comorbidities (DM, HTN, CAD,

CKD) and medication use (HCQ, tocilizumab, AC and steroids) were accounted for to obtain an adjusted OR (aOR) for
all outcomes. The Hosmer-Lemeshow (HL) goodness-of-fit
test was used to predict the fitness of logistic regression models
for applicability to categorical data. The mean BMI values for
baseline comorbidities, in-hospital complications and clinical
endpoints were also compared for both comparison groups. For
normally and abnormally distributed continuous data, an independent sample t-test and Mann-Whitney U test were utilized,
respectively. A one-way analysis of variance (ANOVA) was
used to compare differences in the mean of continuous variables for multiple in-hospital complications. A two-sided α of
less than 0.05 was considered statistically significant corroborating inference from a 95% confidence interval (CI). Statistical
analyses were performed using the SPSS software (version 25).

Results
Demographics and baseline characteristics
A total of 176 consecutive patients (137 with BMI < 34.9 and
39 with BMI > 35) were included. The mean age for lower
BMI vs. higher BMI groups was 64.8 vs. 62.6 (P = 0.02), respectively. The baseline comorbidities across all groups were
comparable except that the lower BMI group had a higher percentage of chronic obstructive pulmonary disease (COPD) (P
= 0.01) and DM (0.046). The proportion of other comorbidities and medication use (HCQ, tocilizumab, AC, steroids) were
comparable across both groups (P ≥ 0.05) (Fig. 1 and Table 1).
Mean differences in BMI across outcomes
The mean BMI for patients who were alive (153/176) at the
7-day of hospitalization was 30.2 ± 8.9 compared to a BMI
of 35.4 ± 13.8 for patients who died (23/176). The mean difference of BMI was -5.15 (95% CI: -9.5 to -7.4), significantly
lower in patients who were alive (P = 0.022). Similarly, 60/176
patients who were intubated had a higher BMI of 33.9 ± 11.2
compared to non-intubated patients (n = 116/176, BMI: 29.2 ±
8.4). The mean difference in the BMI was significantly lower in the non-ventilated group (-4.7 (-7.7 to -1.7) P = 0.002).
There was no significant difference in the BMI of patients receiving HCQ vs. no HCQ (P = 0.21), tocilizumab vs. no tocilizumab (P = 0.44), or AC (P = 0.14). Similarly, a higher BMI
was not associated with an increased risk of new-onset kidney
failure requiring dialysis (P = 0.29) or an upgrade to the critical
care unit (P = 0.14) (Fig. 2, Table 2).
The incidence of in-hospital COVID-19 related complications was rare and not significantly impacted by BMI (P =
0.65). The mean BMI for patients developing deep vein thrombosis (DVT), pulmonary embolism (PE), sepsis, acute kidney
injury (AKI), atrial fibrillation (AF), junctional rhythm and
bleeding was 24.50 ± 2.12 kg/m2, 30.33 ± 5.51 kg/m2, 27.89
± 14.87 kg/m2, 38.27 ± 17.70 kg/m2, 31.50 ± 6.32 kg/m2 and
21.0 kg/m2, respectively. Intriguingly, the BMI for the patient
developing cardiac arrest and AF was 52 kg/m2 (Supplementa-
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Figure 1. Baseline characteristics of patients in different groups. CAD: coronary artery disease; COPD: chronic obstructive
pulmonary disease; CKD: chronic kidney disease; HTN: hypertension; DM: diabetes mellitus; HCQ: hydroxychloroquine; AC:
anticoagulation.

Table 1. Baseline Characteristics of the Included Population Across Comparison Groups
BMI < 34.9

BMI > 35

P value

Male

76 (88.4%)

10 (11.6%)

0.001*

Female

61 (67.8%)

29 (32.2%)

CAD

24 (77.4%)

7 (22.6%)

0.95

COPD

14 (58.3%)

10 (41.7%)

0.013*

CKD

22 (68.8%)

10 (31.3%)

0.171

HTN

85 (74.6%)

29 (25.4%)

0.155

DM

43 (69.4%)

19 (30.6%)

0.046*

Tocilizumab

23 (71.9%)

9 (28.1%)

0.369

HCQ

109 (75.7%)

35 (24.3%)

0.146

Steroids

19 (63.3%)

11 (36.7%)

0.036*

AC

23 (67.6%)

11 (32.4%)

0.111

*P < 0.05. BMI: body mass index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; HTN:
hypertension; DM: diabetes mellitus; HCQ: hydroxychloroquine; AC: anticoagulation.

Figure 2. Forest plots comparing in-hospital endpoints across high and lower BMI groups. BMI: body mass index.
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Table 2. Mean BMI Values Across Different Outcomes and Medication Groups
Outcome

N

BMI, mean ± SD

Mean difference (95% CI)

P value

Alive

155

30.2 ± 8.9

-5.15 (-9.5 to -7.4)

0.022

Death

21

35.4 ± 13.8

No dialysis

166

30.6 ± 9.8

-3.3 (-9.6 to 2.90)

0.29

Dialysis

10

34.0 ± 6.6

No ventilator

116

29.2 ± 8.4

-4.7 (-7.7 to -1.7)

0.002

Ventilator

60

33.9 ± 11.2

No upgrade

120

30.1 ± 9.9

-2.2 (-5.3 to 0.82)

0.14

Upgrade

56

32.3 ± 9.1

No AC

142

30.3 ± 9.5

-2.7 (-6.4 to 9.0)

0.14

AC

34

33.1 ± 6.1

No steroids

146

29.8 ± 8.6

-5.8 (-9.6 to -2.09)

0.002

Steroids

30

35.7 ± 13

No tocilizumab

144

30.5 ± 10.3

-1.45 (-5.2 to 2.3)

0.44

Tocilizumab

32

32.0 ± 6.3

No HCQ

32

27.2 ± 6.17

-4.3 (-8.09 to -0.68)

0.21

HCQ

144

31.6 ± 10.20

SD: standard deviations; CI: confidence interval; BMI: body mass index; HCQ: hydroxychloroquine; AC: anticoagulation.

ry Material 1, www.jocmr.org). Similarly, there was no significant difference in the mean values of inflammatory markers
and laboratory investigations of patients with higher and lower
BMI (Supplementary Material 2, www.jocmr.org).
ORs of outcomes
The unadjusted OR for patients with a higher BMI requiring
IMV (56% vs. 28%, OR: 3.3, 95% CI: 1.6 - 7.0, P = 0.002)
and upgrade to ICU (46% vs. 28%, OR: 2.2, 1.07 - 4.6, P =
0.04) were significantly higher compared to patients with a
lower BMI. Similarly, patients with a higher BMI had higher
in-hospital mortality (21% vs. 9%, OR: 3.2, 95% CI: 1.3 - 8.2,

P = 0.01) compared to patients with a normal BMI. Despite
a numerical advantage in the lower BMI group, there was no
significant difference between the two groups in terms of the
need for dialysis (5% vs. 13%, OR: 3.8, 13% vs. 4%, 1.1 14.1, P = 0.07).
A multivariate regression model was used to adjust the
observed ORs for baseline comorbidities and medications, including DM, HTN, CKD, CAD, use of AC at home, HCQ,
tocilizumab, steroids and therapeutic AC during the hospital
stay. The aORs mirrored the overall findings of unadjusted
ORs with one exception. In contrast to the unadjusted OR,
there was no significant difference in the rate of an upgrade to
the ICU for patients with high and low BMI groups (aOR: 1.7,
0.7 - 3.9, P = 0.17) (Fig. 3, Table 3).

Figure 3. Mean BMI values and number of patients across different in-hospital endpoints. BMI: body mass index.
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Table 3. Unadjusted and Adjusted Odds Ratios of Outcomes in Normal and Obese BMI Groups
Outcomes

N

BMI < 34

BMI > 35

Unadjusted odds

P value

Adjusted odds ratio (aOR)

P value

Vent

60

38 (28%)

22 (56%)

OR 3.3 (1.6 - 7.0)

0.002

aOR 2.6 (1.17 - 6.1)

0.01

No vent

116

99 (72%)

17 (44%)

Upgrade

56

38 (28%)

18 (46%)

OR 2.2 (1.07 - 4.6)

0.04

aOR 1.7 (0.7 - 3.9)

0.17

No upgrade

120

99 (72%)

21 (54%)

Dialysis

10

5 (4%)

5 (13%)

OR 3.8 (1.1 - 14.1)

0.07

aOR 3.6 (0.8 - 15.7)

0.08

No dialysis

166

132 (96%)

34 (87%)

Died

23

13 (9%)

10 (21%)

OR 3.2 (1.3 - 8.2)

0.01

aOR 2.9 (1.1 - 6.0)

0.02

Alive

153

124 (91%)

29 (79%)

BMI: body mass index.

Discussion
Our study reveals that obesity is an independent risk factor for
worse outcomes in COVID-19. Patients with a BMI > 35 kg/
m2 have three times higher odds for mortality and respiratory
complications necessitating IMV compared to patients with a
BMI lower than 34.9 kg/m2. There were substantial differences
in the BMIs of patients who survived COVID-19 compared
with those who succumbed to the disease (5.15, P = 0.02). A
similar difference was observed in patients who required mechanical ventilation versus those in whom the disease severity
did not progress as far (4.7, P = 0.002). Although patients with
a higher BMI seemed to have a greater need for higher-level
care, this trend could have been driven by multiple comorbidities as evidenced by an identical aOR (P = 0.14). Partly contributing to this was also the higher tendency to opt for “comfort measures” or “no escalation of care” in obese patients,
precluding an upgrade to the ICU in patients whose clinical
condition otherwise would require it.
Obesity has traditionally been linked to severe respiratory
infections. Previous epidemiological and clinical studies have
shown that obesity increases the rate of hospitalization as well
as death in patients with influenza type A (H1N1) [6-8]. These
findings were later validated by Kwong et al and Maccioni et
al, who also reported that obese patients were more likely to
get hospitalized due to upper and lower respiratory tract complications [7, 8]. With the recent outbreak, early evidence from
China showed a similar association between obesity and COVID-19. Cai et al observed that overweight and obese patients
had two-fold higher odds of suffering from severe pneumonia when controlled for potential confounders [9]. In line with
these studies, our study demonstrated even higher odds for severe respiratory compromise requiring IMV when adjusted for
baseline comorbidities.
It is believed that both mechanical and inflammatory
mechanisms contribute to obesity-related adverse outcomes in
COVID-19. Obesity results in reduced ventilation by reducing diaphragmatic excursion and limiting chest wall mobility.
Additionally, adipose tissue plays a role in immunological
response by producing a variety of adipokines and pro-inflammatory cytokines, including leptin, interleukins 4 and 6,
interferon, tumor necrosis factor, adiponectin, resistin, and
234

visfatin [10, 11]. While our study revealed an increased risk
for IMV and mortality, surprisingly, the inflammatory markers
including mean D-dimer (P = 0.99), ferritin (P = 0.81) and CRP
(P = 0.31) on both day 1 and day 7 of hospitalizations were
not impacted by higher BMI. These findings indicate either
that the respiratory complications and mortality in obesity in
COVID-19 patients could be independent of inflammation or
that inflammatory markers lag behind the said complications.
It may be that more than inflammation, a higher resistance in
their airways, lower lung volumes, and weaker respiratory
muscles due to obesity play a major role in respiratory complications in COVID-19.
Apart from the above-mentioned mechanisms, studies
have shown that viral replication rates are higher in the cells of
patients who are obese compared to those with normal BMI,
contributing to a higher susceptibility to viral infection [12,
13]. Studies done to assess the immune response to vaccination have also shown a consistently poorer response in people
with obesity [14]. This lends further credence to the theory that
adipose tissue driven immunological changes attenuate an effective response to viral infection. A previous analysis of 124
ICU patients with COVID-19 in a French hospital showed a
direct correlation of BMI with IMV (P < 0.01), the requirement
being highest in those with BMI > 35 kg/m2 (85.7%) [15]. Our
findings not only show a similar increase in the need for IMV,
but also highlight three-fold higher odds of in-hospital mortality in patients with high BMI. The association is independent
of age, comorbidities, or therapeutic strategies employed.
We believe that the collision of the COVID-19 pandemic
with the ongoing endemic of obesity poses major clinical challenges for physicians, and has significant logistical implications for the healthcare sector at large. North America and
Western Europe are not only the current hubs of COVID-19
but also have the highest prevalence of obesity [1]. Providing
intensive care, with its attendant high resource consumption,
to these patients represents a challenge for healthcare systems
in these regions. The need for more bariatric beds, mechanical ventilators, expertise in intubation and skilled nursing staff
(required to position and transport obese patients) rises with
each passing day. Severe respiratory complications along with
difficulties faced by obese patients during diagnostic imaging further compromise the medical care of such patients. Our
study highlights the higher risk of adverse outcomes in this pa-
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tient population, allowing physicians to not only anticipate and
prognosticate these unfortunate outcomes but also to inform
decisions about resource allocation.
Limitations
The major limitation of our study was the small sample size from
a single institution. Although the retrospective cohort study design used can estimate associations only; similar to a prospective
design, our study does have the strength of certainty regarding
the temporal sequence of the exposures and outcomes. Likely
due to small sample size, CIs were wide and the threshold of
statistical significance could not be achieved for multiple comparisons. Although the overall findings were adjusted for covariates, including baseline comorbidities and medications, the
impact of unmeasured confounders such as initiation of several
complementary therapies at the treating physician’s discretion,
could not be determined. Moreover, by excluding patients still in
the hospital, the case fatality ratio in our study cannot reflect the
true mortality of COVID-19. Despite the limited sample size, by
adjusting adult patients with the confirmed disease, we believe
our population is representative of the real-world cohort.
Conclusions
In patients with confirmed COVID-19, morbid obesity appears
to be an independent risk factor of high in-hospital mortality
and the need for IMV.

Supplementary Material
Suppl 1. Mean BMI values across in-hospital complications.
Suppl 2. Differences in the lab findings of patients with different BMI.

Acknowledgments
None to declare.

Financial Disclosure
None to declare.

Conflict of Interest
None to declare.

Informed Consent
Not applicable.

Author Contributions
Conceptualization: Waqas Ullah. Data curation and formal
analysis: Sohaib Roomi. Investigation and methodology: Rehan Saeed and Nayab Nadeem. Project administration: Margot
Boigon and Donald C. Haas. Resources, software, supervision
and validation: David L. Fischman and John Madara. Writing
(original draft): Shafaq Tariq and Moataz Ellithi. Writing (review and editing): Shujaul Haq and Ahmad Arslan.

Data Availability
The data supporting the findings of this study are available
from the corresponding author upon reasonable request.

References
1.

World Health Organization. Prevalence of obesity among
adults, BMI ≥ 30, age-standardized Estimates by WHO
region. Available from: https://apps.who.int/gho/data/
view.main.REGION2480A?lang=en. Accessed May 10,
2020.
2. Centers for Disease Control and Prevention. Overweight
& obesity. Updated February 27, 2020. https://www.cdc.
gov/obesity/data/adult.html. Accessed March 18, 2020.
3. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D,
Francois F, Stachel A. Obesity in patients younger than 60
years is a risk factor for COVID-19 hospital admission.
Clin Infect Dis. 2020;71(15):896-897.
4. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, Mylonakis E. Association of obesity
with disease severity among patients with coronavirus
disease 2019. Obesity (Silver Spring). 2020;28(7):12001204.
5. Petrilli CM, Jones SA, Yang J , Rajagopalan H , O’Donnell
L , Chernyak Y , Tobin KA, et al. Factors associated with
hospitalization and critical illness among 4,103 patients
with COVID-19 disease in New York City. medRxiv.
2020.
6. Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, Belay B, et al. Morbid obesity as a risk
factor for hospitalization and death due to 2009 pandemic
influenza A(H1N1) disease. PLoS One. 2010;5(3):e9694.
7. Kwong JC, Campitelli MA, Rosella LC. Obesity and
respiratory hospitalizations during influenza seasons
in Ontario, Canada: a cohort study. Clin Infect Dis.
2011;53(5):413-421.
8. Maccioni L, Weber S, Elgizouli M, Stoehlker AS, Geist
I, Peter HH, Vach W, et al. Obesity and risk of respiratory
tract infections: results of an infection-diary based cohort
study. BMC Public Health. 2018;18(1):271.
9. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, He Q, et al.
Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care. 2020;43(7):13921398.
10. Trayhurn P, Wood IS. Adipokines: inflammation and

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org

235

Impact of BMI on COVID-19
the pleiotropic role of white adipose tissue. Br J Nutr.
2004;92(3):347-355.
11. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an
endocrine organ. Mol Cell Endocrinol. 2010;316(2):129139.
12. Travanty E, Zhou B, Zhang H, Di YP, Alcorn JF, Wentworth DE, Mason R, et al. Differential susceptibilities
of human lung primary cells to H1N1 influenza viruses.
J Virol. 2015;89(23):11935-11944.
13. Huang CG, Lee LA, Wu YC, Hsiao MJ, Horng JT, Kuo
RL, Huang CH, et al. A pilot study on primary cul-

236

J Clin Med Res. 2021;13(4):230-236
tures of human respiratory tract epithelial cells to predict patients' responses to H7N9 infection. Oncotarget.
2018;9(18):14492-14508.
14. Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. Ann Am Thorac Soc.
2017;14(Supplement_5):S406-S409.
15. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette
J, Duhamel A, Labreuche J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195-1199.

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org

